Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialTHERAPEUTIC-EFFICACYEBOLA-VIRUSCORONAVIRUSGS-5734Background No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). ...
Our study is the first randomised, double-blind, placebo-controlled clinical trial assessing the effect of intravenous remdesivir in adults admitted to hospital with severe COVID-19. The study was terminated before attaining the prespecified sample size. In the intention-to-treat population, the prim...
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-1578. doi:10.1016/S0140-6736(20)31022-9 PubMedGoogle ScholarCrossref 8. United States Food and Drug Administration. Remdesivir emergency use ...
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–78. 7. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 — final report. New Engl...
Grein J et al. Compassionate Use of Remdesivir for Patients with Severe COVID-19. NEJM 2020.PMID: 32275812 Wang Y et al. Remdesivir in Adults with Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial. Lancet 2020. ...
Gilead has initiated two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19. These randomized, open-label, multicenter studies began enrolling patients in March 2020 and will enroll a total of approximately 1,000 patients in the initial ph...
FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19)...
This retrospective observational study included adults (≥18 years) with severe COVID-19, radiologically confirmed pneumonia, a need for supplemental oxygen and an interval from symptom onset to enrolment of 10 days or less. All patients were treated with remdesivir for 5 to 10 days, or with ...
And the third randomized clinical trial of adults with severe COVID-19 compared treatment with remdesivir for five days and ten days and found that COVID-19 symptom improvement was similar for those in the five-day group as those in the 10-day group. ...
28-year-old COVID-19 survivor receives 1st double-lung transplant in US Mayra Ramirez was generally healthy prior to becoming infected with the virus. GENEVA - The world's largest randomized trial of COVID-19 treatments found “conclusive evidence” that remdesivir, a drug us...